78 related articles for article (PubMed ID: 19326998)
1. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
Borsetti A; Baroncelli S; Maggiorella MT; Moretti S; Fanales-Belasio E; Sernicola L; Tripiciano A; Macchia I; Michelini Z; Belli R; Farcomeni S; Pavone-Cossut MR; Negri D; Caputo A; Bellino S; Butto S; Titti F; Cafaro A; Ensoli B
Viral Immunol; 2009 Apr; 22(2):117-24. PubMed ID: 19326998
[TBL] [Abstract][Full Text] [Related]
2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
3. Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.
Ridolfi B; Genovese D; Argentini C; Maggiorella MT; Sernicola L; Buttò S; Titti F; Borsetti A; Ensoli B
Virus Genes; 2008 Feb; 36(1):105-15. PubMed ID: 18049888
[TBL] [Abstract][Full Text] [Related]
4. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
5. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
Cafaro A; Bellino S; Titti F; Maggiorella MT; Sernicola L; Wiseman RW; Venzon D; Karl JA; O'Connor D; Monini P; Robert-Guroff M; Ensoli B
J Virol; 2010 Sep; 84(17):8953-8. PubMed ID: 20554774
[TBL] [Abstract][Full Text] [Related]
6. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
[TBL] [Abstract][Full Text] [Related]
7. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
8. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys.
Borsetti A; Baroncelli S; Maggiorella MT; Bellino S; Moretti S; Sernicola L; Belli R; Ridolfi B; Farcomeni S; Negri DR; Cafaro A; Ensoli B; Titti F
Arch Virol; 2008; 153(3):463-72. PubMed ID: 18080858
[TBL] [Abstract][Full Text] [Related]
9. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
[TBL] [Abstract][Full Text] [Related]
10. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
[TBL] [Abstract][Full Text] [Related]
11. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.
Sadagopal S; Amara RR; Montefiori DC; Wyatt LS; Staprans SI; Kozyr NL; McClure HM; Moss B; Robinson HL
J Virol; 2005 Mar; 79(6):3243-53. PubMed ID: 15731219
[TBL] [Abstract][Full Text] [Related]
12. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
[TBL] [Abstract][Full Text] [Related]
13. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
14. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
[TBL] [Abstract][Full Text] [Related]
15. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
16. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection.
Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Pavone-Cossut MR; Macchia I; Farcomeni S; Tenner-Racz K; Racz P; Ensoli B; Titti F
J Med Primatol; 2007 Aug; 36(4-5):180-94. PubMed ID: 17669207
[TBL] [Abstract][Full Text] [Related]
17. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.
Reimann KA; Watson A; Dailey PJ; Lin W; Lord CI; Steenbeke TD; Parker RA; Axthelm MK; Karlsson GB
Virology; 1999 Mar; 256(1):15-21. PubMed ID: 10087222
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).
Cafaro A; Titti F; Fracasso C; Maggiorella MT; Baroncelli S; Caputo A; Goletti D; Borsetti A; Pace M; Fanales-Belasio E; Ridolfi B; Negri DR; Sernicola L; Belli R; Corrias F; Macchia I; Leone P; Michelini Z; ten Haaft P; Buttò S; Verani P; Ensoli B
Vaccine; 2001 Apr; 19(20-22):2862-77. PubMed ID: 11282197
[TBL] [Abstract][Full Text] [Related]
19. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.
Berglund P; Quesada-Rolander M; Putkonen P; Biberfeld G; Thorstensson R; Liljeström P
AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1487-95. PubMed ID: 9390747
[TBL] [Abstract][Full Text] [Related]
20. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
